ストックスクリーナーアプリを入手
640.52
2.92%
-19.29
アフターアワーズ：
643.74
3.22
+0.50%
前日終値:
$659.81
開ける：
$656
24時間の取引高:
368.46K
Relative Volume:
1.44
時価総額：
$38.30B
収益：
$1.86B
当期純損益:
$-40.29M
株価収益率:
-753.55
EPS:
-0.85
ネットキャッシュフロー:
$-1.28B
1週間 パフォーマンス:
-2.40%
1か月 パフォーマンス:
+0.34%
6か月 パフォーマンス:
+38.22%
1年 パフォーマンス:
+71.98%
1日の値動き範囲:
$639.78
$661.22
1週間の範囲:
$639.78
$678.21
52週間の値動き範囲:
$349.86
$678.21
Argen X Se Adr Stock (ARGX) Company Profile
ARGX を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
ARGX
Argen X Se Adr
|
640.52 | 38.30B | 1.86B | -40.29M | -1.28B | -0.85 |
|
VRTX
Vertex Pharmaceuticals Inc
|
422.00 | 108.68B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
681.58 | 74.90B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
246.27 | 31.76B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
111.93 | 26.83B | 3.30B | -501.07M | 1.03B | -2.1146 |
Argen X Se Adr Stock (ARGX) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2024-11-12 | アップグレード | Wolfe Research | Peer Perform → Outperform |
| 2024-11-05 | アップグレード | Scotiabank | Sector Perform → Sector Outperform |
| 2024-11-01 | ダウングレード | Robert W. Baird | Outperform → Neutral |
| 2024-11-01 | アップグレード | William Blair | Mkt Perform → Outperform |
| 2024-10-10 | 再開されました | Raymond James | Strong Buy |
| 2024-10-04 | ダウングレード | Deutsche Bank | Buy → Hold |
| 2024-08-06 | アップグレード | Barclays | Equal Weight → Overweight |
| 2024-07-25 | アップグレード | Deutsche Bank | Hold → Buy |
| 2024-07-23 | アップグレード | Oppenheimer | Perform → Outperform |
| 2024-02-15 | 開始されました | Wolfe Research | Peer Perform |
| 2023-12-20 | ダウングレード | Deutsche Bank | Buy → Hold |
| 2023-12-20 | ダウングレード | William Blair | Outperform → Mkt Perform |
| 2023-07-31 | 開始されました | Scotiabank | Sector Perform |
| 2023-07-24 | ダウングレード | UBS | Buy → Neutral |
| 2023-07-17 | 再開されました | Evercore ISI | Outperform |
| 2023-06-15 | 開始されました | Societe Generale | Sell |
| 2023-05-31 | 開始されました | UBS | Buy |
| 2023-04-25 | 開始されました | Citigroup | Buy |
| 2023-03-14 | アップグレード | Robert W. Baird | Neutral → Outperform |
| 2022-12-07 | 開始されました | William Blair | Outperform |
| 2022-10-12 | 開始されました | Oppenheimer | Perform |
| 2022-07-29 | ダウングレード | Robert W. Baird | Outperform → Neutral |
| 2022-06-28 | 再開されました | Stifel | Buy |
| 2022-05-03 | アップグレード | Morgan Stanley | Equal-Weight → Overweight |
| 2021-12-08 | 開始されました | Wells Fargo | Overweight |
| 2021-11-29 | アップグレード | Piper Sandler | Neutral → Overweight |
| 2021-10-29 | アップグレード | Guggenheim | Neutral → Buy |
| 2021-10-28 | アップグレード | Raymond James | Outperform → Strong Buy |
| 2021-10-07 | 開始されました | Jefferies | Buy |
| 2021-09-23 | アップグレード | Redburn | Neutral → Buy |
| 2021-09-07 | ダウングレード | Morgan Stanley | Overweight → Equal-Weight |
| 2021-07-23 | 開始されました | Deutsche Bank | Hold |
| 2021-07-19 | 再開されました | Wolfe Research | Outperform |
| 2021-06-18 | 開始されました | UBS | Buy |
| 2021-06-04 | 再開されました | Robert W. Baird | Outperform |
| 2021-05-10 | アップグレード | H.C. Wainwright | Neutral → Buy |
| 2021-04-23 | 開始されました | Redburn | Neutral |
| 2021-03-05 | 繰り返されました | H.C. Wainwright | Neutral |
| 2021-02-02 | ダウングレード | Piper Sandler | Overweight → Neutral |
| 2021-01-04 | ダウングレード | Guggenheim | Buy → Neutral |
| 2020-08-25 | 開始されました | Raymond James | Outperform |
| 2020-08-19 | ダウングレード | Evercore ISI | Outperform → In-line |
| 2020-07-29 | 開始されました | H.C. Wainwright | Neutral |
| 2020-02-10 | 開始されました | BofA/Merrill | Buy |
| 2019-11-05 | 開始されました | Credit Suisse | Neutral |
| 2019-10-31 | アップグレード | William Blair | Mkt Perform → Outperform |
| 2019-10-22 | 開始されました | JP Morgan | Overweight |
| 2019-09-27 | 開始されました | Wells Fargo | Market Perform |
| 2019-09-16 | 再開されました | Cowen | Outperform |
| 2019-06-28 | 開始されました | Robert W. Baird | Outperform |
| 2019-01-18 | 再開されました | SunTrust | Buy |
| 2019-01-04 | 開始されました | Morgan Stanley | Overweight |
| 2018-12-17 | 開始されました | Goldman | Buy |
| 2018-12-14 | 開始されました | Wolfe Research | Outperform |
| 2018-06-29 | 開始されました | Nomura | Buy |
| 2018-04-09 | 開始されました | SunTrust | Buy |
| 2018-01-29 | 繰り返されました | JMP Securities | Mkt Outperform |
すべてを表示
Argen X Se Adr (ARGX) 最新ニュース
argenx's SWOT analysis: biotech stock soars on VYVGART success, pipeline promise - Investing.com India
Argenx stock price target raised to $717 by H.C. Wainwright - Investing.com India
Are Medical Stocks Lagging Argenx (ARGX) This Year? - Yahoo Finance
Truist Securities raises argenx stock rating to Buy, says will exceed Vision 2030 - Investing.com
Jefferies raises argenx stock target, reaffirms buy on global sales result - Investing.com
argenx's SWOT analysis: biotech stock soars on vyvgart success - Investing.com
Piper Sandler increases argenx stock price target on revised estimates - Investing.com
Argenx stock soars to all-time high of $645.31 amid robust growth - Investing.com
argenx to Present at 43rd Annual J.P. Morgan Healthcare Conference - GlobeNewswire Inc.
Argenx Secures Japanese Approval for VYVDURA in CIDP Treatment - Yahoo Finance
Weekly Upgrades and Downgrades - InvestorPlace
Argenx stock soars to all-time high of $630.4 amid robust growth By Investing.com - Investing.com South Africa
Argenx stock soars to all-time high of $630.4 amid robust growth - Investing.com
argenx's SWOT analysis: biotech stock soars on VYVGART success - Investing.com
Upcoming Nasdaq-100 changes could boost the stocks of these 11 companies - MSN
Argenx Expands Autoimmune Portfolio With Additional Vyvgart Approvals as Pipeline Develops - Morningstar
Piper Sandler maintains stock target on argenx, cites growth potential - Investing.com
Argenx stock soars to all-time high of $620.29 - Investing.com
10 High Growth Healthcare Stocks to Invest in Now - Insider Monkey
Argenx stock soars to all-time high of $612.64 amid robust growth By Investing.com - Investing.com South Africa
Argenx stock soars to all-time high of $612.64 amid robust growth - Investing.com India
argenx's SWOT analysis: biotech firm's stock soars on VYVGART success - Investing.com
Jefferies reaffirms Buy rating on argenx stock, ups target amid promising trial updates - Investing.com India
Can Argenx stock sustain its autoimmune category dominance? Oppenheimer weighs in - Investing.com
Barclays bullish on argenx stock after positive trial results - Investing.com
Barclays bullish on argenx stock after positive trial results By Investing.com - Investing.com South Africa
argenx shares see price target boosted by Raymond James, Strong Buy rating upheld - Investing.com
10 Biggest Biotechnology Companies - Investopedia
Argenx upgraded at Wolfe on myasthenia gravis dominance - MSN
argenx stock boosted by Wolfe, citing dominance in MG and profitability ahead - Investing.com
Zai Lab and argenx Announce Approval of VYVGART Hytrulo for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) in China - Yahoo Finance
Scotiabank raises argenx stock PT to $715, highlights efgartigimod's potential - Investing.com India
argenx SE's SWOT analysis: biotech stock poised for growth amid challenges - Investing.com
Deutsche Bank raises argenx target by EUR25, acknowledges momentum despite valuation - Investing.com
Argenx shares target raised by H.C. Wainwright, citing strong sales performance - Investing.com
Argenx Q3 Revenue, EPS Beats Excite Bullish Biotech Analysts: 'Most Enviable I&I Pipeline In Entire Industry' - Benzinga
Argenx shares target lifted, overweight on Vyvgart sales beat - Investing.com
argenx stock downgraded after 65% rally, Baird cites limited short-term upside - Investing.com India
William Blair bullish on argenx stock as Vyvgart flexes in CIDP and eyes new horizons - Investing.com India
Raymond James maintains outperform on argenx, cites strong sales - Investing.com India
argenx stock climbs as Truist highlights industry-leading I&I pipeline growth - Investing.com India
Stifel sees upside in argenx stock with robust pipeline and solid 3Q results - Investing.com
Earnings call: argenx sees growth with VYVGART, sets sights on CIDP - Investing.com Nigeria
Earnings call: argenx sees growth with VYVGART, sets sights on CIDP By Investing.com - Investing.com South Africa
Argen X Se Adr (ARGX) 財務データ
収益
当期純利益
現金流量
EPS
1.16%
2.31%
大文字化:
|
ボリューム (24 時間):